Letter to the Editor

Julien Favresse, Marc Elsen, Christine Eucher, Kim Laffineur, Sandrine Van Eeckhoudt, Jean-Baptiste Nicolas, Constant Gillot, Jean-Michel Dogné and Jonathan Douxfils*

Long-term kinetics of anti-SARS-CoV-2 antibodies in a cohort of 197 hospitalized and non-hospitalized COVID-19 patients

<https://doi.org/10.1515/cclm-2020-1736>

Received November 20, 2020; accepted December 2, 2020;
published online December 18, 2020

Keywords: antibody; COVID-19; kinetics; long-term; SARS-CoV-2.

To the Editor,

The quite recent emergence of the SARS-CoV-2 pandemic precludes long-term investigations of the immunologic response towards this new pathogen. Depending on the pathogen, serological persistence has been shown to last for months to years, as for SARS-CoV or other human coronaviruses (HCoV) [1]. Antibody responses to SARS-CoV-2 can be detected in most infected individuals 14 days after the symptom onset [2–4]. Recent reports are inconsistent regarding the persistence of antibodies directed against SARS-CoV-2 [5, 6]. These differences may be explained by multiple reasons but are more probably related to methodological issues than real different immunogenic effects. The aim of this study was to evaluate the long-term kinetics of anti-SARS-CoV-2 antibodies in a population of RT-PCR confirmed positive SARS-CoV-2 subjects and to describe the kinetics of antibodies in hospitalized patients compared to

the one of non-hospitalized patients, including asymptomatic individuals.

A total of 197 patients with a confirmed SARS-CoV-2 RT-PCR were retrospectively included from March 21 to October 27, 2020. Demographic of patient participants are present in Supplementary Table 1. A total of 314 serum samples was analyzed for the detection of anti-SARS-CoV-2 antibodies. The World Health Organization (WHO) clinical progression scale was used to categorize patients according to disease severity (score 1 = asymptomatic, non-hospitalized; score 2–3 = mild disease, non-hospitalized; score >3 = moderate-severe disease, hospitalized) [7]. Information of symptom onset was gathered in clinical files of patients and/or by contacting the medical practitioners. Blood samples were collected into serum-gel or in lithium-heparin plasma tubes (BD Vacutainer® tubes, Becton Dickinson, New Jersey, USA) according to standardized operating procedures. Samples were centrifuged for 10 min at $1,885 \times g$ (ACU Modular® Pre-Analytics, Roche Diagnostics®). The Elecsys anti-SARS-CoV-2 nucleocapsid (NCP) electrochemiluminescent immunoassay (ECLIA) (Cobas e801, Roche Diagnostics®, Basel, Switzerland) for the *in vitro* qualitative detection of total antibodies (IgG, IgM and IgA) to SARS-CoV-2 was used. The test result is given as a cut-off index (COI). According to the manufacturer, a result <1.0 is considered negative while a result ≥ 1.0 is considered positive. An optimized cut-off of 0.165 was also considered based on our previous validation [8] which has been confirmed by a recent study performed by the National SARS-CoV-2 Serology Assay Evaluation Group (i.e. 0.128) [9]. The specificity of the test was excellent in several independent evaluations (99.8–100%) [8–11]. The RT-PCR for SARS-CoV-2 determination in respiratory samples (nasopharyngeal swab samples) was performed on the LightCycler® 480 Instrument II (Roche Diagnostics®) using the LightMix® Modular SARS-CoV E-gene set.

Samples were subdivided according to the following categories since symptom onset, 0–1 week: 44 sera; 1–2 weeks: 30 sera; 2–4 weeks: 60 sera; 4–6 weeks: 18 sera; 6–11 weeks days:

***Corresponding author: Jonathan Douxfils**, Department of Pharmacy, University of Namur 5000 Namur, Belgium; and Qualiblood sa, Namur, Belgium, Phone: +32 81 72 43 91, E-mail: jonathan.douxfils@unamur.be. <https://orcid.org/0000-0002-7644-5298>

Julien Favresse, Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium; and Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Namur, Belgium

Marc Elsen, Christine Eucher and Kim Laffineur, Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium

Sandrine Van Eeckhoudt and Jean-Baptiste Nicolas, Department of Internal Medicine, Clinique St-Luc Bouge, Namur, Belgium

Constant Gillot and Jean-Michel Dogné, Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Namur, Belgium

47 sera; 11–17 weeks: 57 sera; 17–26 weeks: 34 sera and 26–32 weeks: 24 sera. The antibody kinetics was determined separately for hospitalized and non-hospitalized patients. In asymptomatic patients, the day of RT-PCR positivity was used instead of the day of symptom onset. A kinetics for patients that had at least 3 blood sampling with a last collection time at more than 7 weeks since symptom onset was also evaluated separately (10 non-hospitalized and 11 hospitalized patients).

Descriptive statistics were used to analyze the data. The mean COI results (and 95% CI) were plotted against the different timeframes. Sensitivity was defined as the proportion of correctly identified COVID-19 positive patients initially positive by RT-PCR SARS-CoV-2 determination. Smoothing splines with four knots were used to estimate the time kinetics curve in hospitalized (WHO score >3) and non-hospitalized patients (WHO score 2–3). Dunn's multiple comparisons test was used to assess potential differences between sampling timings. Data analysis was performed using GraphPad Prism® software (version 9.0.0, California, USA). p -value < 0.05 was used as a significance level. The study fulfilled the Ethical principles of the Declaration of Helsinki.

In symptomatic patients, a gradual increase in antibody titers up to the last timepoint was observed (Figure 1). We confirm that sampling before 2 weeks does not permit to identify previous or ongoing infection due to insufficient sensitivity. However, within the first week, the positivity trend was higher in hospitalized patients (i.e. 50%) compared to non-hospitalized patients (i.e. 20%), an observation already made by Long et al. [12] and by Gillot et al. [13]. From 4 to 6 weeks, excellent sensitivities were observed (Table 1, Figure 1). Individual results for hospitalized patients were largely above the manufacturer's cut-off. In non-hospitalized patients, one asymptomatic subject did not develop antibodies against the NCP (Figure 1A).

A trend towards higher antibody titers in hospitalized patients was also observed from weeks 6 to 11. The difference was higher if considering weeks 17 to 32 (Figure 1B). Other studies also reported higher levels of antibodies in patients with more severe disease [2, 14–16]. Of the 21 patients for which at least three independent blood drawn were available for a minimal follow-up period of 7 weeks, a decrease in antibody titer was observed for 4 non-hospitalized patients out of 10 (40%). In hospitalized patient, the titer gradually increased to reach a plateau without any decrease ($n=11$; 100%) (Supplementary Figure 1). Nevertheless, the association was not found to be significant in our study ($p>0.05$).

Importantly, the antibody kinetics may vary according to the type of assay considered. Recent studies

Figure 1: Anti-SARS-CoV-2 titers and long-term kinetics. (A) Anti-SARS-CoV-2 titers (mean COI and 95% CI) from symptom onset in hospitalized (blue points) and non-hospitalized (orange points) COVID-19 patients (timeframe in weeks). Grey points correspond to asymptomatic patients that had a positive RT-PCR. (B) Long-term kinetics of anti-SARS-CoV-2 in hospitalized (blue points) and non-hospitalized (orange points) COVID-19 patients (timeframe in weeks). Smoothing splines with four knots were used to estimate the time kinetics curve (mean standard $\pm$ error of the mean). Asymptomatic patients were excluded from the analysis.

are in line with the current results and also found a sustained antibody response against the NCP antigen using the Roche total antibody assay, on a lower follow-up period (i.e. 3–4 months) [15, 17]. A sustained antibody response against the receptor-binding domain (RBD) antigen, as assessed by the Wantai and the Siemens total antibody assays, was also observed up to 4 months [15, 17]. A decrease in anti-RBD IgG and anti-spike IgG levels was similarly observed over a period of up to 5 months in recent reports [6, 14, 15, 18, 19]. A significant decrease in sensitivity was also found using the Abbott assay (NCP IgG), in studies with up to 4 months of follow-up [15, 17].

Table 1: Anti-SARS-CoV-2 titers (mean CI and 95% CI) from symptom onset in hospitalized and non-hospitalized COVID-19 patients.

Time intervals (weeks since symptom onset)		0–1	1–2	2–4	4–6	6–11	11–17	17–26	26–32
Non-hospitalized WHO score 2–3 (+1)	n	14 (+6)	6 (+4)	23 (+2)	13 (+0)	31 (+7)	31 (+8)	24 (+4)	17 (+1)
	Mean (95% CI)	1.0 (–0.4 to 2.4)	7.7 (0 to 15.5)	22.4 (14.8 to 30.0)	41.4 (28.7 to 54.1)	49.1 (33.4 to 64.7)	70.0 (51.5 to 88.5)	80.0 (60.4 to 99.5)	84.8 (44.5 to 125.3)
	Sensitivity (%)	20.0 (5.7–43.7)	90.0 (55.5–99.9)	96.0 (79.7–99.9)	100 (75.3–100)	100 (90.8–100)	97.4 (86.4–99.9)	100 (87.7–100)	100 (81.5–100)
Hospitalized WHO score >3	n	24	20	35	5	9	18	6	6
	Mean (95% CI)	6.7 (–1.6 to 14.9)	9.0 (3.3 to 14.6)	22.1 (14.4 to 30.0)	24.0 (–11.8 to 59.9)	68.5 (46.0 to 90.9)	84.7 (71.7 to 97.7)	117.6 (70.5 to 164.7)	131.2 (80.9 to 181.4)
	Sensitivity (%) (95% CI)	50.0 (29.2–70.1)	85.0 (62.1–96.8)	94.3 (80.8–99.3)	100 (47.8–100)	100 (66.4–100)	100 (81.5–100)	100 (54.1–100)	100 (54.1–100)

Numbers between brackets correspond to asymptomatic patients (WHO score 1). The cut-off used to calculate sensitivity was 0.165.

The sustained antibody response as measured with total antibody assays (NCP and RBD) compared to IgG assays may be due to the additional response of non-IgG antibody iso- types. The reasons for the differences in assay performance over time for assays targeting the same antigen remain however unclear [17]. Whether the antibodies measured with commercial assays has a neutralizing capacity is paramount to indicate the potential level of protective immunity against SARS-CoV-2 infection. Antibody titers generated with avail- able assays correlated differently with neutralizing antibody titers [17, 20–22]. The Roche assay was the weaker predictor of neutralizing capacity ($r=0.56$, $p=0.0001$) compared to the Abbott assay (NCP IgG) ($r=0.69$, $p<0.0001$), Siemens assay (RBD total antibodies) ($r=0.74$, $p<0.001$), and the S1/S2-based DiaSorin assay (S1/S2 IgG) ($r=0.84$, $p<0.0001$) [17]. Jahrs- dörfer et al. and Padoan et al. confirm that the weaker cor- relation was observed using the Roche assay [11, 22], and McAndrews et al. found that 86% of individuals positive for RBD-directed antibodies exhibited neutralizing capacity, whereas only 76% of positive NCP-directed antibodies exhibited neutralizing capacity [23]. The fact that anti-NCP assays have the lowest neutralizing capacity could be ex- pected, as neutralizing antibodies are directed to the spike protein responsible for enabling cell entry. Indeed, a strong correlation between levels of anti-RBD or anti-spike anti- bodies and neutralizing capacity has been found in inde- pendent evaluations [5, 6, 14, 19, 24]. Neutralizing capacity remained robust from 1 to 5 months in several studies [14, 19, 20], although modest declines at 3–5 months were observed by Wajnberg et al. and Isho et al. [5, 18]. Other studies how- ever observed a significant decrease of 2 to 4-fold, in neutralizing capacity up to 3 months [16, 17, 25–27].

It is important to keep in mind that some patients may develop anti-spike or anti-RBD antibodies but may not have detectable neutralizing antibodies. These are only correla- tion studies which are not related to direct measures of neutralizing capacity [17]. The fact that neutralizing anti- bodies constitute a major protective mechanism against SARS-CoV-2 infection deserves that further investigation are done in this area to assess to long-term inhibition capacity of SARS-CoV-2 antibodies [5, 9, 17]. The contribution of B cells and T cells to immunity to SARS-CoV-2 should also be more explored and it seems important to remind that previous exposure to SARS-CoV-2 might not guarantee total immu- nity in all cases since reinfection with SARS-CoV-2 have been described [28, 29].

In conclusion, we found a gradual increase in anti-NCP total antibody titers for up to 32 weeks since symptom onset. Even if some non-hospitalized patients showed a slight tendency towards a decrease of their antibody titer, this study found that detection rates were similar in

hospitalized or non-hospitalized patients after one week from symptom onset and last at least 7.5 months. Although the majority of asymptomatic patients (95%) developed a sustained antibody response, one patient did not develop antibodies 11 weeks after the RT-PCR positivity supporting the claim that caution is advised when interpreting anti-SARS-CoV-2 antibodies in asymptomatic subjects.

Research funding: None declared.

Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Competing interests: Authors state no conflict of interest.

Informed consent: Informed consent was obtained from all individuals included in this study.

Ethical approval: Research involving human subjects complied with all relevant national regulations, institutional policies and is in accordance with the tenets of the Helsinki Declaration (as revised in 2013), and has been approved by the authors' Institutional Review Board or equivalent committee.

References

- Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. *Nat Commun* 2020;11:4704.
- Bohn MK, Loh TP, Wang CB, Mueller R, Koch D, Sethi S, et al. IFCC interim guidelines on serological testing of antibodies against SARS-CoV-2. *Clin Chem Lab Med* 2020;58:2001–8.
- Favresse J, Eucher C, Elsen M, Laffineur K, Dogne JM, Douxfils J. Response of anti-SARS-CoV-2 total antibodies to nucleocapsid antigen in COVID-19 patients: a longitudinal study. *Clin Chem Lab Med* 2020;58:e193-6.
- Favresse J, Cadrobbi J, Eucher C, Elsen M, Laffineur K, Dogne JM, et al. Clinical performances of three fully automated anti-SARS-CoV-2 immunoassays targeting the nucleocapsid or spike proteins. *J Med Virol* 2020. <https://doi.org/10.1002/jmv.26669>.
- Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science* 2020;370:1227–30.
- Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19. *N Engl J Med* 2020; 383:1085–7.
- Characterisation WHOWotC, Management of C-i. A minimal common outcome measure set for COVID-19 clinical research. *Lancet Infect Dis* 2020;20:e192–7.
- Favresse J, Eucher C, Elsen M, Tre-Hardy M, Dogne JM, Douxfils J. Clinical performance of the elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies. *Clin Chem* 2020;66:1104–6.
- National S-C-SAEG. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. *Lancet Infect Dis* 2020;20:1390–400.
- Egger M, Bundschuh C, Wiesinger K, Gabriel C, Clodi M, Mueller T, et al. Comparison of the Elecsys(R) Anti-SARS-CoV-2 immunoassay with the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma. *Clin Chim Acta* 2020;509:18–21.
- Jahrsdorfer B, Kroschel J, Ludwig C, Corman VM, Schwarz T, Korper S, et al. Independent side-by-side validation and comparison of four serological platforms for SARS-CoV-2 antibody testing. *J Infect Dis* 2020. <https://doi.org/10.1093/infdis/jiaa656>.
- Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med* 2020;26:845–8.
- Gillot C, Douxfils J, Cadrobbi J, Laffineur K, Dogne JM, Elsen M, et al. An original ELISA-based Multiplex method for the simultaneous detection of 5 SARS-CoV-2 IgG antibodies directed against different antigens. *J Clin Med* 2020;9. <https://doi.org/10.3390/jcm9113752>.
- Figueiredo-Campos P, Blankenhaus B, Mota C, Gomes A, Serrano M, Ariotti S, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to six months post disease onset. *Eur J Immunol* 2020. <https://doi.org/10.1002/eji.202048970>.
- Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral immune response to SARS-CoV-2 in Iceland. *N Engl J Med* 2020;383:1724–34.
- Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nat Microbiol* 2020;5:1598–607.
- Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, et al. Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. *medRxiv* 2020. <https://doi.org/10.1101/2020.08.05.20169128>.
- Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. *Sci Immunol* 2020;5. <https://doi.org/10.1126/sciimmunol.abe5511>.
- Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. *Sci Immunol* 2020;5:eabe0367.
- Brigger D, Horn MP, Pennington LF, Powell AE, Siegrist D, Weber B, et al. Accuracy of serological testing for SARS-CoV-2 antibodies: first results of a large mixed-method evaluation study. *Allergy* 2020. <https://doi.org/10.1111/all.14608>.
- Kohmer N, Westhaus S, Ruhl C, Ciesek S, Rabenau HF. Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. *J Clin Virol* 2020;129:104480.
- Padoan A, Bonfante F, Pagliari M, Bortolami A, Negrini D, Zuin S, et al. Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity. *EBioMedicine* 2020;62:103101.
- McAndrews KM, Dowlatsahi DP, Dai J, Becker LM, Hensel J, Snowden LM, et al. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with

- implications for COVID-19 immunity. *JCI Insight* 2020;5. <https://doi.org/10.1172/jci.insight.142386>.
24. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Sci Immunol* 2020;5. <https://doi.org/10.1126/sciimmunol.abc8413>.
 25. Crawford KHD, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. *J Infect Dis* 2020. <https://doi.org/10.1093/infdis/jiaa618>.
 26. Prevost J, Gasser R, Beaudoin-Bussieres G, Richard J, Duerr R, Laumaea A, et al. Cross-sectional evaluation of humoral responses against SARS-CoV-2 spike. *Cell Rep Med* 2020;1: 100126.
 27. Wang K, Long QX, Deng HJ, Hu J, Gao QZ, Zhang GJ, et al. Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection. *Clin Infect Dis* 2020. <https://doi.org/10.1093/cid/ciaa1143>.
 28. Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. *Lancet Infect Dis* 2020. [https://doi.org/10.1016/s1473-3099\(20\)30764-7](https://doi.org/10.1016/s1473-3099(20)30764-7).
 29. To KK, Hung IF, Ip JD, Chu AW, Chan WM, Tam AR, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. *Clin Infect Dis* 2020. <https://doi.org/10.1093/cid/ciaa1275>.

Supplementary Material: The online version of this article offers supplementary material (<https://doi.org/10.1515/cclm-2020-1736>).